• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

For Industry

  • Print
  • Share
  • E-mail

What information and types of notifications are provided to sponsors during the human biologic product application review process?

CBER uses the managed review process for both New Drug Applications (NDA) and Biologics License Applications (BLA) to ensure consistency in the process to the extent possible.  The communication timelines, including the initial filing letter with the STN assignment and contract information and other types of notification within each of these phases are outlined in our Guidance for Review Staff and Industry Good Review Management Principles and Practices for PDUFA Products.  More detailed information may be found in our manual of Standard Operating Procedures and Policies.

The communication timelines are goals and other factors may impact FDA’s ability to meet those internal goals.  These timelines may require modification by the review division based on factors such as staffing, competing workload, and complexity of the application.  Such deviations are carefully considered, however, and any new internal timelines are clearly communicated to the review team and applicant by the regulatory project manager (RPM).  Agency contact information for the RPM assigned to each application is provided to the applicant in the acknowledgement letter.

Relevant Resources:

Rate this article: